Randomized phase III trial of the Southern Italy Oncology Group comparing sequential ifosfamide + gemcitabine followed by cisplatin + navelbine (IG -> PN) versus the opposite sequence (PN -> IG) versus cisplatin + navelbine (PN) versus gemcitabine + cisplatin (GP) in stage III–IV non small cell lung cancer (NSCLC)